To order this 330+ page report, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Key Inclusions
§
A detailed assessment
of the current market landscape of targeted protein
degradation-based therapeutics, providing information on drug / therapy developer(s)
(such as year of establishment, company size and location of headquarters),
clinical study sponsor(s) and collaborator(s), type of protein degrader
(degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs,
LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators,
SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of
development (clinical, preclinical, and discovery stage) of product candidates,
target indication(s), key therapeutic area(s), type of target protein(s),
target enzyme(s) (if available), target signaling pathway (if
available), mechanism of action (if available), type of therapy
(monotherapy and combination therapy), route of administration (oral,
intravenous and others), and information on special drug designations (if
any). In addition, the chapter highlights the various technology platforms
that are being actively used for the development of targeted protein degraders.
§
Elaborate profiles of
key players that are engaged in the development of targeted protein degraders (shortlisted
on the basis of phase of development of pipeline products), featuring a
brief overview of the company, its financial information (if available),
detailed descriptions of their respective lead drug candidates, and an informed
future outlook. Additionally, each drug profile features information on the
type of drug, route of administration, target indications, current status of
development and a brief summary of its developmental history.
§
Brief tabulated
profiles of industry players (shortlisted on the basis of the number of
pipeline products), featuring details on the innovator company (such as
year of establishment, location of headquarters, number of employees, and key
members of the executive team), recent developments, along with descriptions of
their respective drug candidates.
§
A detailed clinical
trial analysis of completed, ongoing and planned studies of various targeted
protein degraders, highlighting prevalent trends across various relevant
parameters, such as current trial status, trial registration year, enrolled
patient population and regional distribution of trials, type of protein
degrader, phase of development, study design, leading industry and non-industry
players (in terms of number of trials conducted), study focus, target
therapeutic area, key indications, and clinical endpoints.
§
An assessment of the
relative experience of key opinion leaders (KOLs) within this domain, (shortlisted
based on their involvement in various clinical studies), featuring
detailed 2X2 matrices (based on the strength and activeness of KOLs), a
schematic world map representation (highlighting the geographical locations of
eminent scientists / researchers) and an analysis evaluating the (relative)
level of expertise of different KOLs, based on parameters such as number of
publications, number of citations, participation in clinical trials, number of
affiliations and strength of professional network (based on information
available on ResearchGate).
§
A detailed
publication analysis of more than 210 peer-reviewed, scientific articles that
have been published since 2017, highlighting the research focus within the
industry. It also highlights the key trends observed across the publications,
including information on novel protein degraders, potential target proteins,
target disease indications, and analysis based on various relevant parameters,
such as year of publication, and most popular journals (in terms of number
of articles published in the given time period) within this domain.
§
An analysis of the
partnerships that have been established in the domain, over the period 2014-Q3
2019, covering research agreements, product / technology licensing agreements,
mergers / acquisitions, asset purchase agreements, R&D and
commercialization agreements, IP licensing agreements, clinical trial agreements,
product development agreements, and other relevant deals.
§
An analysis of the
investments made at various stages of development, such as seed financing,
venture capital financing, debt financing, grants / awards, capital raised from
IPOs and subsequent offerings, by companies that are engaged in this field.
The report also features the likely
distribution of the current and forecasted opportunity across important market
segments, mentioned below:
§ Type
of payment of licensing agreements
§ Upfront
payments
§ Milestone
payments
§
Type of protein degrader
§ Degronimids
§ PROTACs
§ SARDs
/ SERDs
§ Specific
BET and DUB inhibitors
§ Other
protein degraders
§
Therapeutic area
§ Neurodegenerative
disorders
§ Oncological
disorders
§ Other
therapeutic areas
§ Route
of administration
§ Oral
§ Intravenous
§ Other
routes
§ Key
geographical region
§ North
America
§ Europe
§ Asia-Pacific
To
request a sample pages, please visit https://www.rootsanalysis.com/reports/289/request-sample.html
Key
Questions Answered
§ What
are the prevalent R&D trends related to targeted protein degradation?
§ Which
clinical conditions can be treated using targeted protein degradation-based
therapeutics?
§ What
are the most popular proteins being targeted by bifunctional degrader
molecules?
§ What
are the key challenges faced by stakeholders engaged in this domain?
§ What
are the key technology platforms that leverage the concept of targeted protein
degradation?
§ Who
are the leading industry and non-industry players in this market?
§ What
are the contributions of big pharma players in this field?
§ What
are the key geographies where research on targeted protein degradation is being
conducted?
§ Who
are the key investors in this domain?
§ Who
are the key opinion leaders / experts in this field?
§ What
kind of partnership models are commonly adopted by industry stakeholders?
§ What
are the factors that are likely to influence the evolution of this upcoming market?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
You may also be
interested in the following titles:
1.
DNA-Encoded
Libraries: Platforms and Services Market
2.
Global
Stem Cells Market: Focus on Clinical Therapies, 2020–2030
3.
The
Human Microbiome Market: Focus on Therapeutics (including gut-brain axis
targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition),
2019-2030
Contact Details:
Gaurav Chaudhary
+1
(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
